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SUMMARY
Itraconazole (ITZ) is a well-known antifungal agent that also has anti-cancer activity. In this 
study, we identified ITZ as a broad-spectrum inhibitor of enteroviruses (e.g. poliovirus, 
coxsackievirus, enterovirus-71, rhinovirus). We demonstrate that ITZ inhibits viral RNA 
replication by targeting oxysterol-binding protein (OSBP) and OSBP-related protein 4 (ORP4). 
Consistently, OSW-1, a specific OSBP/ORP4 antagonist, also inhibits enterovirus replication. 
Knockdown of OSBP inhibits virus replication whereas overexpression of OSBP or ORP4 
counteracts the antiviral effects of ITZ and OSW-1. ITZ binds OSBP and inhibits its function, i.e. 
shuttling of cholesterol and phosphatidylinositol-4-phosphate between membranes, thereby likely 
perturbing the virus-induced membrane alterations essential for viral replication organelle 
formation. ITZ also inhibits hepatitis C virus replication, which also relies on OSBP. Together, 
these data implicate OSBP/ORP4 as novel molecular targets of ITZ and point to an essential role 
of OSBP/ORP4-mediated lipid exchange in virus replication that can be targeted by antiviral 
drugs.
INTRODUCTION
The family Picornaviridae contains many important human and animal pathogens. The 
genus Enterovirus includes poliovirus (PV), coxsackievirus (CV), echovirus, several 
numbered enteroviruses (e.g. enterovirus-71, EV71) and human rhinovirus (HRV). Except 
for PV, no vaccines are available to prevent infections with enteroviruses and no antiviral 
drugs are available for treatment. Other important human picornaviruses include hepatitis A 
virus and human parechovirus (HPeV). Well-known animal pathogens are foot-and-mouth 
disease virus (FMDV) and encephalomyocarditis virus (EMCV).
The genome of enteroviruses consists of a 7.5-kb single-stranded RNA molecule of positive 
polarity [(+)RNA]. It encodes a single polyprotein that is proteolytically processed by the 
viral proteases into the structural proteins (VP1-VP4) and the non-structural proteins (2A–
2C and 3A–3D). The viral genome is replicated by assemblies of viral and host proteins 
located on intracellular membranes termed replication organelles (ROs). The ROs are 
formed as a result of virus-induced remodeling of secretory pathway membranes, which 
most likely starts at the Golgi complex (Hsu et al., 2010), eventually resulting in a complex 
network of tubulovesicular membranes (Belov et al., 2012; Limpens et al., 2011). Viral 
modification of lipid homeostasis is thought to play a major role in RO formation. Viral 
proteins 2BC and 3A play a major role in the membrane rearrangements by recruiting 
essential host factor for enterovirus replication to ROs, such as phosphatidylinositol-
phosphate-4-kinase III beta (PI4KIIIβ), a Golgi-localized lipid kinase that generates 
phosphatidylinositol-4 phosphate (PI4P) (Arita, 2014; Hsu et al., 2010). The functional 
importance of elevated PI4P levels at ROs remains to be established. The viral RNA-
dependent RNA-polymerase, 3Dpol, binds PI4P in vitro, but it is unknown whether this is 
important for its recruitment and/or activation in infected cells (Hsu et al., 2010). 
Alternatively, the PI4P lipids may participate in RO formation by facilitating the recruitment 
of PI4P-binding host proteins with membrane-modifying properties.
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Cholesterol is a critical membrane component that determines membrane fluidity and 
regulates the formation and function of membrane-bound complexes of lipids and proteins. 
Several (+)RNA viruses, such as hepatitis C virus (HCV), dengue and West Nile virus, 
remodel the cellular cholesterol landscape to make intracellular host cell membranes 
conducive for efficient genome replication (Rothwell et al., 2009; Wang et al., 2014). 
Enterovirus-induced rearrangements of secretory pathway membranes into the 
tubulovesicular RO structures may also depend on alterations in cholesterol homeostasis. 
Recent data suggest that enteroviruses stimulate clathrin-mediated endocytosis to transport 
cholesterol from the plasma membrane and extracellular medium to ROs (Ilnytska et al., 
2013). However, other intracellular cholesterol trafficking pathways may also be subverted 
by enteroviruses to create their ROs.
Recently, oxysterol-binding protein (OSBP) was show to play a key role in the transport of 
cholesterol and PI4P between ER and Golgi (Mesmin et al., 2013). OSBP links ER and 
trans-Golgi membranes at so-called ER-Golgi membrane contact sites (MCS) and shuttles 
sterol into the Golgi and PI4P back to the ER, where it is hydrolyzed by the PI4P-
phosphatase Sac1. This cholesterol/PI4P exchange cycle drives the delivery of sterol in the 
trans-Golgi and self-regulates the localization of OSBP on the Golgi. OSBP and the OSBP-
related proteins (ORPs) constitute a family of related proteins that, based on gene structure 
and sequence, can be subdivided into six subfamilies. OSBP and its closest relative ORP4 
(also called OSBP2) belong to subfamily I. All ORPs have a lipid-binding domain that was 
initially thought to be specific for sterols. However, recent structural analysis suggests that 
ORPs have the ability to bind PI4P and a second lipid that is either a sterol or a non-sterol 
ligand. Many ORPs, including OSBP, have an FFAT-motif that is recognized by ER-
resident VAP receptors and an N-terminal pleckstrin homology (PH) domain for binding 
PI4P, through which they are linked to a variety of organelles. Although the functions of 
most ORPs are not very well understood, it has become clear that ORPs execute diverse 
functions in lipid sensing, lipid transport and cell signaling (Raychaudhuri and Prinz, 2010; 
Weber-Boyvat et al., 2013).
We set out to identify novel inhibitors of enterovirus replication by screening the NIH 
Clinical Collection (NCC), a library of FDA-approved drugs that have a history of use in 
clinical trials for treatment of a wide variety of diseases. Similar collections of FDA-
approved drugs have proven to be rich sources of undiscovered bioactivity and therapeutic 
potential. We identified itraconazole (ITZ) as a broad-spectrum inhibitor of enterovirus 
replication. ITZ is a well-known antifungal drug that inhibits CYP51, a cytochrome P450 
required for sterol biosynthesis (Lestner and Hope, 2013). In addition, ITZ exerts anti-cancer 
activity by inhibiting angiogenesis – through disturbing mTOR signaling and vascular 
endothelial growth factor receptor 2 (VEGFR2) trafficking – and the Hedgehog (Hh) 
signaling pathway (Kim et al., 2010; Nacev et al., 2011; Xu et al., 2010). ITZ has been 
found to be efficacious in patients with several cancer types in multiple Phase 2 clinical 
studies (Antonarakis et al., 2013; Kim et al., 2014; Rudin et al., 2013). We demonstrate that 
known targets of ITZ cannot explain the antiviral activity of ITZ. Instead, evidence is 
presented that OSBP and ORP4 are novel targets of ITZ and that direct binding of ITZ to 
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OSBP – which localizes at ROs – disrupts its lipid shuttling function and accounts for the 
antiviral effect of ITZ.
RESULTS
ITZ is an inhibitor of Enterovirus and Cardiovirus replication
We performed a screen of the NCC to identify novel inhibitors of CVB3 replication. Like all 
enteroviruses, CVB3 kills its host cell, and thereby causes a ‘cytopathic effect’ (CPE). We 
screened the NCC by microscopically observing which compounds prevented the 
development of CPE in a multi-cycle replication assay and identified ITZ (Figure S1) as one 
of the hits. To determine its spectrum of antiviral activity, we tested ITZ against a 
representative panel of picornaviruses in a multi-cycle CPE-reduction assay. ITZ exhibited 
antiviral effect against all enteroviruses examined (belonging to several species) with EC50 
values between 0.3 µM and 1.6 µM (Table S1). In addition, EMCV, a Cardiovirus genus 
member, was inhibited by ITZ. In contrast, equine rhinitis A virus (ERAV, Aphthovirus 
genus member) and HPeV-1 (Parechovirus genus member) were insensitive to ITZ. To 
exclude the possibility that the antiviral activity was due to toxic side effects, we determined 
the effect of ITZ on virus production during a single replication cycle. Similar to the multi-
cycle CPE-reduction assay, ITZ was active against CVB3, EV71, HRV14, and EMCV, but 
not ERAV, in a single replication cycle (Figure 1A) without apparent toxicity (Figure 1B). 
ITZ also inhibited Saffold virus (SAFV) replication, a human cardiovirus (Figure 1A). Thus, 
ITZ exerts broad antiviral activity against enteroviruses and cardioviruses.
ITZ inhibits viral RNA genome replication
Next, we determined the effect of ITZ on translation and replication of transfected CVB3 
and EMCV RNAs, namely a subgenomic replicon of CVB3, in which (part of) the capsid-
coding region is replaced by a firefly luciferase gene, or a genomic RNA of EMCV, in 
which a Renilla luciferase gene is inserted upstream of the coding region. As positive 
controls we used guanidine-HCl and dipyridamole, well-known and potent inhibitors of 
CVB3 and EMCV replication respectively. Two hours after transfection of the RNAs, when 
no RNA replication has taken place yet (Van Kuppeveld et al., 1995), luciferase levels were 
unaffected, indicating that ITZ does not inhibit viral genome translation (Figure 1C). 
However, at later time points luciferase production by both replicons was decreased, 
demonstrating that ITZ affects RNA replication. Importantly, ITZ did not affect viral 
polyprotein synthesis and processing (Figure S2).
Inhibition of virus replication is independent of known targets of ITZ
ITZ is widely used as an antifungal drug that inhibits the fungal enzyme CYP51. ITZ has 
also been shown to have some inhibitory activity towards the human CYP51 (hCYP51) and 
the related cytochrome P450 CYP3A4. In addition to ITZ, other azole family antifungal 
drugs, including posaconazole, ketoconazole, fluconazole and voriconazole (Figure S1), also 
inhibit hCYP51 and CYP3A4 with slightly lower or similar potency as ITZ (Warrilow et al., 
2013; Zhang et al., 2012). We tested whether these drugs exert antiviral activity using 
recombinant viruses RLuc-CVB3 and RLuc-EMCV, which carry the Renilla luciferase gene 
upstream of the coding region. At 10 µM, only posaconazole inhibited replication of RLuc-
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CVB3 and RLuc-EMCV. The remaining azoles did not display any antiviral activity at 
concentrations up to 100 µM (Figures 2A and S3A–C). Similar results were obtained in a 
multi-cycle CPE-reduction assay (not shown). These results ruled out the possibility that 
inhibition of hCYP51 or CYP3A4 underlies the antiviral activity of ITZ and its structurally 
related analog posaconazole.
As ITZ also inhibits the Hedgehog (Hh) signaling pathway, most likely by interfering with 
the function of the G-protein-coupled receptor-like protein Smoothened (Kim et al., 2010), 
we tested several Smoothened antagonists in the viral luciferase assays. The Smoothened 
antagonists KAAD-cyclopamine, Sant-1, and Sant-2 (Chen et al., 2002; Taipale et al., 2000) 
had no effect on the replication of RLuc-CVB3 or RLuc-EMCV (Figure 2B and Figure 
S3D), indicating that the antiviral activity of ITZ is not mediated by its inhibition of the Hh 
pathway.
The anti-angiogenic activity of ITZ has been attributed at least in part to its inhibition of the 
mTOR signaling pathway through disruption of the shuttling of cholesterol between plasma 
membrane and late endosomes/lysosomes, thereby inducing the accumulation of cholesterol 
in the endolysosomal system (Xu et al., 2010). We found that cholesterol, stained with 
filipin, was not only redistributed by ITZ and posaconazole but also by ketoconazole (which 
does not inhibit virus replication) in two human cell lines [HAP1 (Figure 2C) and HeLa R19 
cells (Figure S3E)]. Moreover, the mTOR inhibitor rapamycin had no effect on picornavirus 
replication (Beretta et al., 1996; Wong et al., 2008). Together, these results suggest that 
inhibition of virus replication by ITZ or posaconazole is not due to disruption of endosomal 
cholesterol shuttling or the cholesterol-related mTOR inhibition.
In addition to the aforementioned molecular and pathway targets of ITZ, ITZ has been 
reported to disturb N-glycosylation (Nacev et al., 2011). However, the N-glycosylation 
inhibitor tunicamycin did not affect poliovirus (Doedens et al., 1997) or CVB3 replication 
(our data not shown). ITZ has also been shown to antagonize the estrogen receptor α (ERα) 
(Cheng et al., 2012). But ERα agonist β-estradiol did not affect CVB3 (Figure 2D) or 
EMCV replication (Figure S3F). Finally, ITZ has been reported to target p-glycoprotein, 
UDP-glucuronosyltransferase, and ERβ, none of which are likely to mediate the antiviral 
activity of ITZ, because these are as potently inhibited by ketoconazole (Cheng et al., 2012; 
Walsky et al., 2012; Wang et al., 2002b), which did not affect virus replication.
Mutations in 3A that confer resistance to PI4KIIIβ inhibitors also confer resistance to ITZ, 
but ITZ does not inhibit PI4KIIIβ activity
As a first step to identifying the antiviral target of ITZ, we studied its effect on replication of 
CVB3 mutant viruses that we previously selected for resistance against other inhibitors. 
CVB3 carrying mutation 3A[H57Y] – which confers resistance to PI4KIIIβ inhibitors (e.g. 
PIK93, enviroxime, GW5074) (Van der Schaar et al., 2012) – proved less sensitive to ITZ 
than wt CVB3 in both a single-cycle replication assay (Figure 2E) and in a multicycle CPE-
reduction assay (Figure 2F). Other mutations in 3A that were shown to protect against 
PI4KIIIβ inhibitors (i.e. V45A and I54F) (Van der Schaar et al., 2012), also provided cross-
resistance to ITZ (Figure 2G). Similarly, mutation A70T in PV 3A, which was also shown to 
protect against PI4KIIIβ inhibitors (Arita et al., 2009), protected PV against ITZ (Figure 
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2H). These results imply a link between 3A, PI4P lipids, and the mechanism of antiviral 
action of ITZ.
To determine whether ITZ inhibits PI4KIIIβ activity, we transiently transfected cells with a 
genetically encoded PI4P-sensor, i.e. the GFP-tagged PH domain of FAPP1 (FAPP1-PH-
GFP). Localization of this sensor specifically depends on activity of PI4KIIIβ (Balla et al., 
2005; Van der Schaar et al., 2012). In control cells, FAPP1-PH-GFP overlapped with the 
Golgi-localized PI4KIIIβ (Figure 2I). Upon treatment with a PI4KIIIβ inhibitor, PIK93, 
FAPP1-PH-GFP was redistributed to the cytosol. ITZ, however, did not decrease FAPP1-
PH-GFP localization. In fact, ITZ caused a small increase in the amount of Golgi-localized 
FAPP1-PH-GFP, which was more apparent in a cell line stably expressing this PI4P sensor 
(which showed a more homogenous and moderate expression level) (Figure S4A). Also 
upon staining PI4P with a specific antibody, a PI4KIIIβ inhibitor, BF738735 (Van der 
Schaar et al., 2013), decreased PI4P levels, whereas ITZ increased PI4P levels (Figure S4B).
CVB3 replication is not completely blocked by ITZ (see e.g. Figures 1A and 2E), thus 
permitting the monitoring of PI4P lipids in treated cells. Both in untreated and ITZ-treated 
cells infected with CVB3 (visualized using 3A antibody), PI4P levels (visualized using PI4P 
antibody) were clearly increased compared to uninfected cells (Figure S4C), indicating that 
ITZ also does not inhibit PI4KIIIβ activity in infected cells.
ITZ inhibits virus replication by targeting OSBP and ORP4
Having ruled out PI4KIIIβ as a target of ITZ, we next turned to signaling steps downstream 
of PI4P, i.e., proteins that bind to PI4P lipids. To assess whether any of the known PI4P-
binding proteins could be a target of ITZ, we performed a target identification by siRNA 
sensitization (TISS) assay (Arita et al., 2010). TISS encompasses siRNA knockdown of 
candidate target proteins to potentiate the biological effect of a low concentration of a 
compound. Among a number of PI4P-binding, Golgi-localized proteins, knockdown of 
OSBP, but not any of the other PH domain-containing proteins, enhanced the inhibitory 
effect of a low concentration (1.25 µM) of ITZ on PV replication (Figure 3A), implying 
OSBP as a possible antiviral target of ITZ. We further assessed this possibility by several 
experiments. First, the OSBP antagonist OSW-1 (Burgett et al., 2011) potently inhibited 
CVB3 replication (Figure 3B), confirming that pharmacological targeting of OSBP can 
inhibit enterovirus replication. As for ITZ, the 3A[H57Y] mutation in CVB3 provided 
resistance against OSW-1 (Figure 3B). Akin to ITZ, OSW-1 inhibited all enteroviruses 
tested as well as EMCV, but not ERAV (data not shown). Importantly, OSW-1 did not 
affect endolysosomal cholesterol distribution (Figure 3C), supporting our previous 
conclusion that this effect unlikely explains the antiviral effect of ITZ. Second, similar as for 
PV (Wang et al., 2014) siRNA knockdown of OSBP inhibited replication of EV71 and 
HRV2 (Figure 3D). CVB3 replication was also inhibited by OSBP knockdown but this 
difference was not statistically significant, in line with the lower sensitivity of CVB3 than 
EV71 to ITZ (Figure 1A). Third, overexpression of OSBP restored replication of CVB3 and 
EV71 in the presence of both ITZ or OSW-1 (Figure 3E), confirming that inhibition of viral 
replication by ITZ and OSW-1 is mediated through OSBP. Overexpression of PI4KIIIβ 
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failed to rescue replication, nor did OSBP overexpression provide rescue against PI4KIIIβ 
inhibitors (data not shown), indicating the specificity of the experimental setup.
Besides OSBP, OSW-1 also targets ORP4 (Burgett et al., 2011). Knockdown of ORP4, but 
none of the other ORPs, also sensitized PV to ITZ (Figure 3F) and overexpression of ORP4 
counteracted the inhibitory effect of OSW-1 on CVB3 and EV71 replication (Figure 3G). 
We also attempted to test the effect of ORP4 depletion. Although in the TISS assay, ORP4 
KD potentiated the effect of ITZ, we were not able to achieve robust knockdown (>75% at 
mRNA level) and therefore we cannot conclude unambiguously whether ORP4 is important 
for virus replication. Problems with ORP4 knockdown were also observed by others and are 
likely due to an essential role of ORP4 in cell proliferation and survival (Charman et al., 
2014). Collectively, these results indicate that both OSBP and ORP4 are novel targets of 
ITZ and are involved in its mechanism of antiviral action.
ITZ inhibits in vitro HCV replication
Replication of HCV also requires OSBP and is inhibited by OSW-1 (Wang et al., 2014). In 
line with our findings for enteroviruses, we found that ITZ and posaconazole, but not the 
other selected azoles, inhibited HCV replication in cell culture (Figure S6). EC50 values for 
inhibition of HCV replication by ITZ were comparable to those obtained for the 
enteroviruses (Table S1). Together, our data clearly demonstrate that ITZ inhibits OSBP 
function and that viruses from different families that depend on OSBP function can be 
inhibited by ITZ. Importantly, not all (+)RNA viruses are sensitive to inhibition of OSBP. 
Dengue virus replication was recently observed to be insensitive to OSW-1 (Wang et al., 
2014) and we showed that also replication of mouse hepatitis virus (a coronavirus) is 
insensitive to OSW-1 and ITZ (data not shown).
Treatment with ITZ results in relocalization of OSBP to the Golgi complex
After having established that OSBP and – possibly – ORP4 are novel targets of ITZ, we 
wanted to study how ITZ targets these proteins. Because of available tools, we focused on 
OSBP for the remainder of this study. In line with published data (Burgett et al., 2011), 
OSW-1 caused a massive recruitment of overexpressed GFP-OSBP to the Golgi apparatus 
(as marked by staining endogenous PI4KIIIβ) (Figure 4A). A similar relocalization was 
observed for endogenous OSBP (Figure 4B). ITZ and posaconazole, but not the azoles that 
lacked antiviral activity, redistributed OSBP in a manner that is similar to OSW-1. Live-cell 
imaging was performed to study the dynamics of GFP-OSBP relocalization by the 
compounds. Before addition of the compounds, GFP-OSBP primarily localized in the 
cytosol with a Golgi pattern faintly visible. A few minutes after the addition of the 
compounds, GFP-OSBP fluorescence at the Golgi was clearly increased in cells treated with 
either ITZ or OSW-1 and continued to increase at the expense of the cytoplasmic signal 
(Figures 4C–D and Movie S1). OSW-1 was previously reported to disrupt the structure of 
the Golgi apparatus (Burgett et al., 2011), which we also observed from ~30–60 min onward 
as GFP-positive punctae that became more numerous over time (Figure 4C). In ITZ-treated 
cells, the Golgi pattern became affected only hours later and appeared less dispersed than 
that in OSW-1 treated cells.
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ITZ directly inhibits lipid shuttling by OSBP
To investigate whether ITZ can block the lipid transfer activity of OSBP, we used a set of in 
vitro liposomal assays (Mesmin et al., 2013) (Supplemental Experimental Procedures) to 
measure the transport of dehydroergosterol (DHE) (Figure 5A) and PI4P (Figure 5D) 
between ER-like and Golgi-like liposomes. ITZ inhibited the sterol transfer activity of 
purified OSBP in a dose-dependent manner with an IC50 of ~200nM (Figure 5B). At 1 µM, 
ITZ and posaconazole, but not the other selected azoles, strongly inhibited DHE transfer 
transport in this liposomal assay, although they were less potent than the known OSBP 
ligand 25OH (Figure 5C). We also observed a dose-dependent inhibition of PI4P transfer by 
ITZ (IC50 = ~4 µM) (Figure 5E). Posaconazole slightly inhibited PI4P, whereas the other 
azoles showed no activity (Figure 5F). For unknown reasons, a stimulatory effect of 25OH 
on PI4P transfer was observed, which depended on the 2% cholesterol content of the ER-
like liposomes. The IC50 values suggest that ITZ is more potent towards sterol than PI4P 
transfer. Importantly, for technical reasons the sterol and PI4P shuttling assays are 
performed under different conditions and therefore cannot be directly compared. Further 
investigations would be needed to establish whether ITZ indeed more potently inhibits sterol 
than PI4P shuttling.
ITZ may inhibit the lipid transfer functions of OSBP directly by inhibiting the function of 
the ORD, which transfers the lipids, or indirectly by disrupting the binding of OSBP to the 
liposomes. To investigate whether ITZ inhibits binding of OSBP to the liposomes, we 
studied whether it interferes with the interactions between i) the FFAT-motif and VAP-A on 
the ER-like liposomes and ii) the PH-domain and PI4P on the Golgi-like liposomes. To this 
end, we performed liposomal float-up experiments using a recombinant fragment of OSBP 
containing the PH-domain and FFAT-motif (aa 76–408; PH-FFAT) (Figures 5G and 5I). In 
the presence of VAP-A, PH-FFAT bound to the ER-like liposomes and this interaction was 
not disrupted by 1 µM ITZ (Figure 5H). The interaction of PH-FFAT with PI4P-containing 
Golgi-like liposomes was not disrupted by 10 µM ITZ either (Figure 5J). Likewise, VAP-A 
interaction with PH-FFAT recruited to Golgi-like liposomes was also insensitive to 10 µM 
ITZ (Figure 5J). Together, the liposomal float-up assays show that ITZ does not interfere 
with the binding of OSBP to the liposomes via VAP-A and PI4P.
To establish whether ITZ inhibits the lipid transfer activity of the ORD, we made use of a 
previously established assay (Mesmin et al., 2013). Limited tryptic proteolysis of OSBP 
cleaves OSBP into three major fragments; a ~43kDa fragment containing the PH-domain 
and FFAT-motif, and two fragments of ~35kDa and ~20kDa that are derived from the ORD. 
Previously, it was shown that the ORD-derived fragments retain lipid transfer activity, also 
in the absence of the inactive ~43kDa fragment (Mesmin et al., 2013). We found that ITZ 
still inhibited both DHE (Figure 5K) and PI4P (Figure 5L) transfer by OSBP that had been 
subjected to tryptic proteolysis (Figure S7A). These results suggest that ITZ inhibits both the 
sterol- and PI4P-transfer activities of OSBP by targeting the ORD.
ITZ binds directly to OSBP
The inhibitory effect of ITZ on OSBP function in a minimal in vitro system implied that ITZ 
directly inhibits OSBP. To biochemically define the binding in more detail, we measured 
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binding of ITZ to GFP-OSBP using MicroScale Thermophoresis. Each molecule or complex 
distributes differently in a temperature field, depending on size, charge and the hydration 
shell. Binding of ITZ to OSBP will affect the hydration shell and thereby its thermophoretic 
behavior. ITZ altered the thermophoretic profiles of purified GFP-OSBP (Figures S7B–C) in 
a dose-dependent manner, indicating direct binding. Normalization and fitting of data from 
three independent measurements demonstrated that ITZ binds to OSBP with a Kd of ~430 
nM (Figure 5M). The monophasic shape of the binding curve indicates that there is likely 
only a single binding site for ITZ on OSBP, although our data cannot rule out that there are 
two sites with nearly identical Kd’s.
OSBP localizes to ROs in a PI4P-dependent manner
To test whether OSBP plays a role in formation and/or maintenance of the ROs, we 
examined its localization in infected cells. In uninfected cells, OSBP is mainly distributed 
throughout the cytosol with some OSBP localized to the Golgi apparatus (Figure 6A), where 
it co-localized with PI4KIIIβ and the trans-Golgi network marker TGN46 (data not shown). 
In infected cells, OSBP localization was markedly changed, i.e. the Golgi pattern was lost 
and OSBP appeared in dispersed structures throughout the cytoplasm where it co-localized 
with viral protein 3A as a marker for ROs (Manders’ coefficient for overlap of 3A with 
OSBP: 0.36) (Figures 6A–B). To examine whether OSBP localized to ROs in a PI4P-
dependent manner, cells were infected with CVB3 and replication was allowed to progress 
uninhibited for 4.5 hr before the PI4KIIIβ inhibitor BF738735 was added for 30 min, after 
which cells were processed for microscopy. Inhibition of PI4KIIIβ decreased co-localization 
of OSBP with 3A (Manders’ coefficient: 0.11), whereas treatment with ITZ increased co-
localization of OSBP with the RO-marker 3A (Manders’ coefficient: 0.62) (Figures 6A–B). 
The enhanced recruitment of OSBP to ROs upon ITZ treatment is reminiscent of the 
enhanced Golgi-localization of OSBP upon treatment of ITZ or other OSBP inhibitors, and 
may therefore be caused by an inhibition of PI4P removal from ROs.
ITZ inhibits PI4P and cholesterol shuttling at ROs
To test directly whether ITZ inhibits the PI4P shuttling function of OSBP at ROs, cells were 
infected with CVB3 and replication was allowed to progress uninhibited for 3 hr. Then ITZ 
or BF738735 were added for 1 hr, the cells were processed for microscopy and the PI4P 
intensity at ROs was quantified. ITZ treatment caused a strong increase in PI4P signal at the 
ROs (~50% increase), whereas BF738735 treatment reduced it by ~50% (Figures 7A–B), in 
line with the effects of these drugs on OSBP recruitment (Figure 6A). No such effects on 
PI4P were observed upon treatment with guanidine, an inhibitor of the viral 2C protein, 
which was included to rule out that the observed effects were merely due to an inhibition of 
replication. Thus, these results demonstrate that in infected cells ITZ prevents the removal of 
PI4P from ROs, which is comparable to our observations in uninfected cells (Figures 2I, 
S4A–B).
To test whether ITZ also inhibits cholesterol shuttling to ROs, cells were infected and 
treated similar as described above, cholesterol was visualized by filipin staining and the co-
localization of filipin with 3A was quantified using a Pearson’s correlation coefficient. In 
DMSO-treated cells, filipin partially overlapped with 3A (Pearson’s 0.53). ITZ significantly 
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reduced the co-localization of filipin with 3A (Pearson’s 0.38), indicating that ITZ inhibited 
the redistribution of cholesterol to the ROs (Figures 7C–D). Similarly, BF738735, which 
reduces the localization of OSBP to ROs (Figure 6A), also inhibited cholesterol shuttling to 
ROs (Pearson’s 0.35), whereas guanidine did not decrease the overlap between filipin and 
3A. Thus, we demonstrate that OSBP is recruited to ROs through the action of PI4KIIIβ and 
that ITZ inhibits both the PI4P and the cholesterol transfer functions of OSBP in infected 
cells.
DISCUSSION
Enteroviruses alter cellular lipid homeostasis and remodel host cell membranes into 
replication organelles by usurping a number of host proteins, such as PI4KIIIβ (Arita et al., 
2011; Hsu et al., 2010). However, as yet little is known about the underlying mechanisms 
and the identity of other host factors involved. Elucidation of the mechanism of action of 
inhibitors of virus replication has proven instrumental in obtaining novel insights into the 
mechanisms of viral replication. In this study we identified ITZ, a widely used antifungal 
drug that is currently also being explored as an anti-cancer agent, as a novel, broad-spectrum 
inhibitor of enteroviruses, cardioviruses and HCV. We show that none of the well-
established targets of ITZ (i.e. hCYP51, mTOR, VEGFR2, Hh) explains its antiviral 
activity. Instead, we identified the PI4P-binding proteins OSBP and ORP4 as novel targets 
of ITZ through which the antiviral effect is mediated.
OSBP is a master regulator of lipid homeostasis at MCS between the ER and the trans-Golgi 
apparatus. It exchanges cholesterol and PI4P between these membranes and has been 
proposed to control MCS stability (Mesmin et al., 2013). OSBP is the prototype member of 
the family of ORPs, a group of proteins whose cellular functions have remained poorly 
understood. We identified OSBP and ORP4 as targets of ITZ. Pharmacologic inhibition, 
siRNA knockdown and rescue of replication by overexpression demonstrate the importance 
of these proteins for virus replication. Furthermore, OSBP localized to ROs in a PI4KIIIβ- 
and PI4P-dependent manner. ITZ directly bound purified OSBP and inhibited both the 
cholesterol and PI4P-transport activities of OSBP in vitro (in liposomal assays). Also in 
living (uninfected) cells, ITZ inhibited the transport function of OSBP (i.e. transport of 
cholesterol from ER to Golgi and transport of PI4P from Golgi to ER), leading to an 
increase in PI4P levels at the Golgi, thereby causing the accumulation of OSBP. Likewise, 
in infected cells ITZ increased PI4P levels on ROs, again leading to an enhanced recruitment 
of OSBP, and inhibited the accumulation of cholesterol on ROs. Thus, we demonstrate that 
ITZ inhibits the lipid shuttling functions of OSBP not only in vitro, but also in both infected 
and uninfected cells.
The enteroviral proteins 2BC and 3A play a critical role in RO formation by recruiting 
PI4KIIIβ, which leads to the accumulation of PI4P lipids on ROs (Arita, 2014; Arita et al., 
2011; Hsu et al., 2010). We here show that OSBP is subsequently recruited to ROs via PI4P. 
Our data indicate that at ER-RO MCS, OSBP exchanges PI4P for cholesterol, either newly 
synthesized in the ER or originating from a lipid droplet storage pool and being mobilized 
through the ER, leading to an accumulation of cholesterol at the ROs (Arita, 2014). Our 
findings are in agreement with those of a recent paper that suggested that OSBP shuttles 
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cholesterol to HRV ROs based on the inhibitory effects on HRV replication of OSBP 
knockdown and 25OH treatment (Roulin et al., 2014). The finding that the levels of 
cholesterol are elevated at the expense of cholesterylesters (i.e. the form in which cholesterol 
is stored in lipid droplets) in enterovirus-infected cells (Ilnytska et al., 2013; Roulin et al., 
2014), suggests that stored cholesterol is mobilized for transport to ROs. In addition, uptake 
of cholesterol by endocytosis has been suggested to contribute to the accumulation of 
cholesterol at ROs (Ilnytska et al., 2013). The role of cholesterol accumulation at ROs is far 
from established. Cholesterol is of profound importance for membranes properties such as 
membrane fluidity and formation of lipid microdomains, and is thereby likely important for 
the membrane rearrangements and deformations underlying RO formation. In addition, 
cholesterol alterations have been suggested to affect viral polyprotein processing efficiency 
(Ilnytska et al., 2013).
The activity of OSBP is also important for the homeostasis of other lipids. At ER-Golgi 
MCS, it acts in concert with the PI transfer protein Nir2, which supplies PI for PI4P 
synthesis at Golgi membranes, and CERT, which transfers ceramide to Golgi for 
sphingomyelin synthesis, thereby generating diacylglycerols (DAGs) (Peretti et al., 2008). 
Importantly OSBP-ligands, e.g. 25OH and OSW-1, change the localization of CERT and 
modify sphingomyelin synthesis (Burgett et al., 2011; Perry and Ridgway, 2006). As an 
inhibitor of OSBP-mediated lipid shuttling, ITZ may thus not only affect the accumulation 
of cholesterol, but also perturb the homeostasis of other lipids, such as sphingomyelin and 
DAGs. Whether and how this contributes to the inhibition of RO formation and/or function 
remains to be established.
Our study and the work by Arita et al. (2013) implicate a role for ORP4 in addition to OSBP 
in enterovirus replication. Unfortunately, little is known about the biological function of 
ORP4. Roles for ORP4 are proposed in organization of the cytoskeletal vimentin network, 
cell proliferation and survival, and sterol transfer (Charman et al., 2014; Wang et al., 2002a). 
However, unlike OSBP, ORP4 does not localize to the Golgi under normal conditions or in 
response to a ligand such as 25OH (Charman et al., 2014; Wang et al., 2002a). It therefore 
seems unlikely that ORP4 transports cholesterol between ER and Golgi in a similar manner 
as OSBP. How ORP4 overexpression can counteract the inhibitory effect of ITZ on virus 
replication thus remains to be established. It is possible that OSBP-ORP4 heteromultimers 
(Wyles et al., 2007) are important for virus replication, but this requires further 
investigation. Besides OSBP and ORP4, other ORPs did not appear to be targeted by ITZ, 
though they may still be important for virus replication.
ITZ has been shown to inhibit angiogenesis (via mTOR and VEGFR2) and growth of Hh-
dependent cancer cells, but the exact molecular mechanisms of the anti-tumor activities of 
ITZ await elucidation. It remains to be established whether OSBP inhibition contributes to 
the anti-cancer activities of ITZ via these pathways. OSBP overexpression, which we 
showed to counter the antiviral activity of ITZ, failed to prevent the inhibitory effects of ITZ 
on mTOR and Hh signaling (not shown). These observations suggest that ITZ does not 
inhibit these anti-tumor pathways through OSBP, however, we cannot exclude that the 
overexpression approach can only neutralize the antiviral effect of ITZ. Therefore, more 
work is needed to establish whether or not ITZ exerts its anti-tumor activities via OSBP 
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and/or ORP4. OSW-1 and several other natural products were recently reported to inhibit 
the growth of cultured human cancer cell lines through OSBP and ORP4, and therefore 
collectively termed ORPphilins (Burgett et al., 2011). Our data that ITZ targets OSBP and 
ORP4 justify classifying ITZ as a novel ORPphilin. It is plausible that ITZ inhibits OSBP/
ORP4-dependent cancer cell growth and survival in a manner independent of, and in 
addition to, mTOR, VEGFR2 and Hh. Recently, two inhibitors of PV replication were 
shown to target OSBP and ORP4 (Arita et al., 2013), although binding to OSBP has yet to 
be shown, and may therefore also classify as ORPphilins.
In conclusion, we identified ITZ as a broad-spectrum inhibitor of enterovirus, cardiovirus 
and HCV replication that exerts its antiviral activity through the novel targets OSBP and 
ORP4, presumably by inhibiting the lipid shuttling functions of OSBP. Together, our study 
provides novel insight into enterovirus replication and presents ITZ, OSW-1 and other 
ORPphilins, as potential novel inhibitors to treat enterovirus infections.
EXPERIMENTAL PROCEDURES
Details about published and standard methods (cell culture, plasmids, virus infections, 
replicon transfections, the TISS assay, rescue experiments, analysis of viral polyprotein 
processing, siRNA experiments, immunofluorescence microscopy and liposomal assays) are 
provided in the Supplemental Experimental Procedures.
Reagents
The following compounds were purchased: itraconazole (Santa Cruz Biotechnology); 
posaconazole (Merck); ketoconazole (Enzo Life Sciences); fluconazole and voriconazole 
(Pfizer); T-00127-HEV1 (Pharmeks Ltd.); dipyridamole, guanidine hydrochloride (GuHCl) 
and β-estradiol (Sigma Aldrich); Sant-1, Sant-2 (Tocris Bioscience); cyclopamine-KAAD 
(Calbiochem). PIK93 was a kind gift from Dr. K. Shokat, UC Berkeley, USA, BF738735 
(MacLeod et al., 2013) was provided by Galapagos NV, Mechelen, Belgium, and OSW-1 
was isolated from nature (Burgett et al., 2011). β-estradiol was dissolved according to the 
manufacturer’s instructions, GuHCl was dissolved in water and all other compounds in 
DMSO.
Compound library screen
The NIH Clinical Collection was purchased from the NIH. The 446 highly drug-like 
compounds were screened for inhibitors of CVB3 using reduction of CPE as readout. 
Subconfluent monolayers of BGM cells in 96-well plates were infected with 10 CCID50 of 
CVB3 per well, compounds were added to a final concentration of 10 µM and the level of 
CPE was visually assessed after two days of incubation at 37°C when full CPE had 
developed in the infected, untreated control wells.
Live-cell imaging
For live-cell imaging experiments HeLa R19 cells were transfected with pEGFP-hOSBP, 
treated with ITZ, OSW-1 or solvent control (DMSO), and imaged using a Nikon A1R 
confocal laser scanning microscope. Images were processed and quantified using the Nikon 
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NIS-Elements software. For additional details, see the supplemental experimental 
procedures.
MicroScale Thermophoresis (MST)
The interaction between ITZ and recombinant GFP-hOSBP-SII (human OSBP with an N-
terminal GFP and a C-terminal Strep-tagII) was investigated by MST using a NanoTemper 
Monolith NT.115 instrument and the NTAnalysis software (NanoTemper Technologies).
Statistical analyses
Data are presented as means ± SEM. Replication data were analyzed by pair-wise 
comparisons of conditions using one-tailed Student’s t-test. Statistics significance is 
indicated as * p<0.05, ** p<0.01, *** p<0.001.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. ITZ inhibits viruses at the genome replication stage
(A) BGM (CVB3, EV71, EMCV, ERAV) or HeLa R19 cells (HRV14, SAFV) were infected 
with virus at MOI 1 and treated with ITZ. Virus titers at 8 hr p.i. (10 hr for SAFV) were 
determined by endpoint dilution. (B) Cell viability with MTS assay after 8 hr incubation 
with ITZ. (C) BGM cells were transfected with RNA of subgenomic replicons pRib-LUC-
CB3/T7 or pRLuc-M16.1 (EMCV), treated with DMSO, 25 µM ITZ, or as positive controls 
2 mM GuHCl or 80 µM dipyridamole, and luciferase levels were determined at the indicated 
time points. Experiments were performed in triplicate and mean values ± SEM are shown, 
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asterisks indicate statistical significance compared to mock treated controls. See also Figures 
S1 and S2.
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Figure 2. ITZ does not inhibit virus replication through known targets or PI4KIIIβ, although 
CVB3 with mutations in the non-structural viral protein 3A are cross-resistant to ITZ and 
PI4KIIIβ inhibitors
(A, B, D) HeLa R19 (A) or BGM (B, D) cells were infected with RLuc-CVB3 at MOI 0.1, 
treated with 10 µM ITZ, DMSO, or 10 µM antifungal azoles (A), Hedgehog pathway 
antagonists (100nM Sant-1, Sant-2, or cyclopamine-KAAD) (B), or ERα (β-estradiol) (D), 
and Renilla luciferase levels were measured after 6 hr. (C) HAP1 cells were treated with 10 
µM antifungal azoles for 6 hr, fixed and cholesterol was stained with filipin. (E) BGM cells 
were infected, treated and analyzed as in (A) with RLuc-CVB3 wt or the 3A[H57Y] mutant. 
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(F) BGM cells were infected with CVB3 wt or CVB3 3A[H57Y] at low MOI in the 
presence of ITZ and cell viability was measured after three days. (G–H) In vitro transcribed 
RNA of subgenomic replicons pRib-LUC-CB3/T7 (wt and indicated 3A mutants) (G) or 
pPV-FLuc (wt and 3A[A70T]) (H) was transfected into RD cells, the cells were treated with 
DMSO, 25 µM ITZ or 1.5 µM T-00127-HEV1 (PI4KIIIβ inhibitor) and firefly luciferase 
levels at 7 hr p.i. were determined. (I) HeLa R19 cells were transfected with FAPP1-PH-
GFP treated with DMSO, 25 µM ITZ, or 1 µM PIK93 for 1 hr and stained with an antibody 
against PI4KIIIβ and Hoechst. Experiments were performed in triplicate and shown are 
mean values ± SEM, asterisks indicate statistical significance compared to mock treated 
controls (A, B) or of mutant virus compared to wt. Scale bars correspond to 10µm. See also 
Figures S3 and S4.
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Figure 3. ITZ inhibits virus replication by targeting OSBP and ORP4
(A) HEK293 cells were transfected with siRNAs targeting PI4P-binding proteins, infected 
with PV and incubated in the presence of 1.25 µM ITZ. Normalized PV infection represents 
the level of firefly luciferase activity at 7 hr p.i. for siRNA-transfected and compound-
treated cells divided by the firefly luciferase activity measured in siRNA-transfected and 
untreated cells. (B) HeLa R19 cells were infected with RLuc-CVB3 wt or the 3A[H57Y] 
mutant at MOI 0.1, treated with OSW-1 and Renilla luciferase levels were determined after 
7 hr. Cell viability was determined in parallel. (C) HAP1 cells were treated for 6 hr with 10 
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nM OSW-1 or 10 µM ITZ, fixed and stained with filipin. (D) HeLa R19 cells were 
transfected with constructs encoding OSBP or EGFP (negative control) for 24 hr, infected 
with RLuc-CVB3 at MOI 0.25 or EV71 at MOI 1 and treated with 10 µM (CVB3) or 3 µM 
(EV71) ITZ, 3 nM OSW-1 or DMSO. Renilla luciferase levels were determined at 7 hr p.i. 
(CVB3) or virus titers at 10hrs p.i. were determined by endpoint titration (EV71). (E) HeLa 
R19 cells were transfected with siRNAs against OSBP, PI4KIIIβ (positive control), or a 
scrambled siRNA for 2 days, infected with CVB3, EV71, or HRV2 at MOI 1 and virus titers 
at 10 hr p.i. were determined by endpoint titration. Knockdown efficiency was determined 
by Q-PCR and immunofluorescence (Figure S5), and an MTS assay was used to test for 
effects on cell viability. (F) HEK293 cells were transfected with siRNAs targeting ORP 
family members (roman numbering indicates ORP subfamilies), infected, treated with ITZ 
and analyzed as in (A). (G) HeLa R19 cells were transfected with constructs encoding 
OSBP, ORP4 or EGFP, infected and treated with 3 nM OSW-1, and data were analyzed as 
in (C). All Figures are representative examples of experiments that were performed in 
triplicate. Shown are mean values ± SEM. Scale bars correspond to 10µm. See also Figures 
S5 and S6.
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Figure 4. Azoles that inhibit virus replication rapidly accumulate OSBP at the Golgi
(A) HeLa R19 cells were transfected with OSBP-GFP, treated with DMSO, 10 µM of ITZ or 
antifungal azoles or 10 nM OSW-1 for 1 hr, fixed and counterstained with an antibody 
against PI4KIIIβ and DAPI. (B) HeLa R19 cells were treated as in (A), fixed and 
immunostained for endogenous OSBP. (C) HeLa R19 cells were transfected with GFP-
OSBP, treated with DMSO, 10 µM of ITZ or 10 nM OSW-1, and the relocalization of OSBP 
was imaged by live-cell CLSM. Cells were imaged overnight. During the first 30 minutes, 
images were taken as fast as possible (~1.5 minute intervals), then intervals were stepwise 
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increased to 30 min from 3.5 hr onward. Representative groups of cells are shown. The 
images are frames from Supplementary Movie 1. (D) Quantification of the relative GFP-
OSBP signal at the Golgi apparatus in 5 cells for each condition from panel (C). Scale bars 
correspond to 10µm. See also Supplementary Movie 1.
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Figure 5. ITZ binds OSBP and inhibits sterol and PI4P transfer by OSBP
(A–F) The effect of ITZ, antifungal azoles, or positive (25OH) or solvent controls (DMSO) 
on in vitro OSBP-mediated transfer of the fluorescent cholesterol analog DHE (A–C) or 
PI4P (D–F) was tested using liposomal assays depicted in panels A and D. In both cases, 
initial exchange rates were determined in the presence of increasing concentrations of ITZ 
(B, E) or in presence of 1 µM of the indicated drugs and then plotted in bar diagram (C, F). 
(G–J) The effect of ITZ on binding of an N-terminal OSBP fragment (aa 76–408; PH-
FFAT) to ERlike (G–H) and Golgi-like (I–J) liposomes was examined by liposomal float-up 
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assays as outlined in panels G and I. Liposomal fractions were analyzed for binding of 
proteins by SDS-PAGE (H, J). (K–L) The effect of ITZ and control compounds on DHE (K) 
or PI4P (L) transfer by trypsinized OSBP was studied as with full-length OSBP (panels A–
F). (M) The interaction of ITZ with GFP-tagged OSBP was investigated using MST. Data 
from three separate measurements were normalized, plotted and a sigmoidal dose-response 
curve was fitted. Statistical significance for the drug-treated conditions was calculated 
compared to the ‘No drug’ control. See also Figure S7.
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Figure 6. ITZ affects OSBP localization in infected cells
(A) BGM cells were infected with CVB3 at MOI 10. At 4.5 hr p.i., cells were treated for 30 
min with DMSO as vehicle control, 1 µM BF738753 (BF; a PI4KIIIβ inhibitor), or 10 µM 
ITZ. At 5 hr p.i., cells were fixed, processed for immunofluorescence with antibodies 
against OSBP and viral protein 3A, and imaged using CLSM. (B) Manders’ coefficients for 
overlap of 3A with OSBP were calculated for DMSO (12 cells), BF (7 cells) and ITZ (10 
cells).
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Figure 7. ITZ inhibits PI4P and cholesterol shuttling in infected cells
(A) BGM cells were infected with CVB3 at MOI 10. At 3hr p.i., cells were treated for 1 hr 
with DMSO, 2 mM guanidine HCl (Gua), 1 µM BF738735 (BF), or 10 µM ITZ. At 4 hr p.i., 
cells were fixed, processed for immunofluorescence with antibodies against 3A and PI4P, 
imaged by wide-field microscopy and deconvoluted. (B) PI4P intensity at 3A-positive 
structures was calculated for DMSO (11 cells), Gua (13 cells), BF (12 cells) and ITZ (11 
cells). (C) HeLa R19 cells were infected with CVB3 at MOI 10. At 3hr p.i., cells were 
treated for 1 hr with DMSO, 2 mM Gua, 1 µM BF, or 10 µM ITZ. At 4 hr p.i., cells were 
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fixed, processed for immunofluorescence with an antibody against 3A and filipin to stain 
cholesterol, imaged by wide-field microscopy and deconvoluted. (D) Pearson’s correlation 
coefficients for overlap of filipin and 3A were calculated for DMSO (17 cells), Gua (15 
cells), BF (18 cells) and ITZ (19 cells). Shown are means ± SEM. Scale bars correspond to 
10µm.
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